UPDATE | January 20, 2026
Seamless technology transfer: Accelerating biologics from drug substance to drug product
Samsung Biologics has supported biologics developers for more than a decade, building a reputation as a reliable CDMO partner that reduces operational complexity, accelerates regulatory pathways, and helps deliver therapies to patients worldwide.
Our end-to-end tech transfer framework standardizes workflows and embeds right-first-time principles into every project, helping clients advance their programs efficiently while maintaining high product quality and regulatory confidence.
Our end-to-end tech transfer framework standardizes workflows and embeds right-first-time principles into every project, helping clients advance their programs efficiently while maintaining high product quality and regulatory confidence.
Samsung Biologics has supported biologics developers for more than a decade, building a reputation as a reliable CDMO partner that reduces operational complexity, accelerates regulatory pathways, and helps deliver therapies to patients worldwide.
Our end-to-end tech transfer framework standardizes workflows and embeds right-first-time principles into every project, helping clients advance their programs efficiently while maintaining high product quality and regulatory confidence.
Related Content